Cases & Deals

Celgene files patent infringement charges against Actavis and Abrika over generic versions of ADHD drug Focalin XR®

Clients Celgene Corporation

Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action involving Celgene's branded ADHD drug Focalin XR®. This matter concluded through a mutually agreeable settlement.

Celgene Corporation, et al. v. Actavis South Atlantic, LLC and Abrika Pharmaceuticals, Inc., Case No. 3-07-cv-05367 (D.N.J.) (Judge Wolfson)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.